| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Labcorp Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$221.49 |
| 52 Week High | US$238.48 |
| 52 Week Low | US$192.43 |
| Beta | 1.04 |
| 11 Month Change | -3.31% |
| 3 Month Change | 7.59% |
| 1 Year Change | 7.48% |
| 33 Year Change | -24.85% |
| 5 Year Change | 32.63% |
| Change since IPO | 25.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0JSY | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | -0.3% | -0.3% | -0.6% |
| 1Y | 7.5% | -12.0% | 5.4% |
Return vs Industry: 0JSY exceeded the UK Healthcare industry which returned -12% over the past year.
Return vs Market: 0JSY exceeded the UK Market which returned 5.4% over the past year.
Price Volatility
| 0JSY volatility | |
|---|---|
| 0JSY Average Weekly Movement | 3.5% |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0JSY has not had significant price volatility in the past 3 months.
Volatility Over Time: 0JSY's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 61,975 | Adam Schechter | www.labcorp.com |
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
Labcorp Holdings Inc. Fundamentals Summary
| 0JSY fundamental statistics | |
|---|---|
| Market cap | US$18.66b |
| Earnings (TTM) | US$449.50m |
| Revenue (TTM) | US$12.49b |
41.5x
P/E Ratio1.5x
P/S RatioIs 0JSY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0JSY income statement (TTM) | |
|---|---|
| Revenue | US$12.49b |
| Cost of Revenue | US$8.99b |
| Gross Profit | US$3.50b |
| Other Expenses | US$3.05b |
| Earnings | US$449.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.35 |
| Gross Margin | 28.00% |
| Net Profit Margin | 3.60% |
| Debt/Equity Ratio | 64.2% |
How did 0JSY perform over the long term?
See historical performance and comparison